Panitumumab and cetuximab were obtained from the MSK Hospital Pharmacy. Rovalpituzumab (SC16.56) was synthesized and produced as recombinant protein based on the sequence disclosed in U.S. patent US9089616B2 (Genscript). J591 was a generous gift of Professor Neil Bander at Weill Cornell [28 (link)]. The antibodies were conjugated with the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS; Macrocyclics) and then radiolabeled with zirconium-89 (89Zr) following previously reported methods [19 (link), 33 (link), 42 (link)–46 (link)]. [89Zr]Zr-DFO-antibody radiochemical purity (RCP) was determined by instant thin-layer chromatography and used for in vitro and in vivo studies.
Protocol detail
Radiolabeling of Antibodies with Zirconium-89
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Antibodies
Antibody
Based sequence
Cetuximab
J591
Panitumumab
Radiochemical
Recombinant protein
Thin layer chromatography
Zirconium 89
Corresponding Organization : Cornell University
Top 5 similar protocols
Protocol cited in 1 other protocol
Variable analysis
independent variables
- Panitumumab
- Cetuximab
- Rovalpituzumab (SC16.56)
- Radiochemical purity (RCP) of [89Zr]Zr-DFO-antibody
- Methods for conjugation of the antibodies with the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS)
- Methods for radiolabeling the antibodies with zirconium-89 (89Zr)
- None specified
- None specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!